Sirtris PHarma Sets IPO Terms

Sirtris Pharmaceuticals Inc., a Cambridge, Mass.-based developer of therapeutics that modulate an enzyme family called sirtuins, has set its proposed IPO terms to 5 million common shares being offered at between $9 and $11 per share. It plans to trade on the Nasdaq under ticker symbol SIRT, with JPMorgan serving as lead underwriter. Sirtris has raised $67 million in VC funding since its 2002 inception (plus $15m in venture debt), from firms like Polaris Venture Partners (14.91% pre-IPO stake), TVM (11.83%), Cardinal Health Partners (9.52%), Skyline Ventures (7.68%) Wellcome Trust (5.13%), Three Arch Partners, Novartis, Cargill Ventures, Cyad Group, Hunt Ventures, Red Abbey, Bessemer Venture Partners, Genzyme Ventures, QVT Fund and Alexandria Real Estate Equity. www.sirtrispharma.com